Pacific Biosciences of California, Inc. (PACB) Operating margin 2016–2025
Pacific Biosciences of California, Inc. (PACB) operating margin by fiscal year — reported operating income divided by reported revenue.
-346.2%FY2025 · since FY2016: -78.5% → -346.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -346.2% | -38.2 pp |
| FY2024 | -308.0% | -141.2 pp |
| FY2023 | -166.8% | +72.6 pp |
| FY2022 | -239.4% | -78.2 pp |
| FY2021 | -161.2% | -28.9 pp |
| FY2020 | -132.3% | -21.7 pp |
| FY2019 | -110.6% | +17.8 pp |
| FY2018 | -128.4% | -32.4 pp |
| FY2017 | -96.1% | -17.5 pp |
| FY2016 | -78.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PACB financial trends
PACB RevenuePACB Net incomePACB Net marginPACB Gross profitPACB Gross marginPACB Operating incomePACB Operating cash flowPACB Free cash flowPACB Capital expendituresPACB Return on equityPACB Stock buybacksPACB Dividends paidPACB Total assetsPACB Total liabilitiesPACB Shareholders’ equityPACB overview →